ROLE OF VILDAGLIPTIN- DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN PATIENTS WITH TYPE 2 DIABETES MELLITUS - AN OVERVIEW
Revathi Pitchaipillai*, Bhuvaneswari Shanmugasundaram, Sarojini Kaliyaperumal, Jeyaseelan Senthinath and Manickavasagam Subramania Pillai
ABSTRACT
Diabetes is a condition in which the body does not produce or respond to insulin, a hormone that regulates the level of sugar in the blood. It is characterized by abnormally high levels of glucose in the blood. They are classified into three categories Type 1 Diabetes mellitus (DM), Type 2 Diabetes mellitus (DM) and Gestational diabetes. The prevalence of T2DM is increasing rapidly and plays a vital role in the genesis of the pathophysiological events. Oral hypoglycemic agents are used in the treatment of T2DM and they have their own limitations.
Newer drugs have been invented for the treatment of T2DM. Dipeptidyl peptidase 4 (DPP-4) inhibitors plays an important role in the treatment of T2DM. There are six DPP-4 inhibitor identified (Sitagliptin, Vildagliptin, Saxagliptin, Alogliptin, Linagliptin and teneligliptin). Vildagliptin is a second DPP-4 inhibitor approved by US FDA in February 2007. It is an orally active, potent, and selective DPP-4 inhibitor shown to be effective and well tolerated by patients with T2DM. It is rapidly and well absorbed with an oral bioavailability of 85 %. It is effective either as monotherapy or in combination with other antidiabetic agents. It has got lower incidence of hypoglycemic symptoms when used as a monotherapy or combination therapy with other oral hypoglycemic drugs. Vildagliptin once daily or twice daily is found to be an effective, safety and well tolerated DPP-4 inhibitor as monotherapy or combination therapy with oral hypoglemic agents (OHA) or insulin in the treatment of T2DM patients.
Keywords: Vildagliptin, diabetes mellitus, therapeutic management.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
